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Sarcomatoid carcinoma (SC) of prostate gland is a rare biphasic tumour. In about half of cases, initial diagnosis is acinar
adenocarcinoma, followed by nonsurgical therapy, with a subsequent diagnosis of SC. The survival rate is lower. We report a
case of an 59-years-old man with unusual histopathologic ﬁnding of prostate sarcomatoid carcinoma, showing characteristics
of ductal prostatic adenocarcinoma and prostatic stromal sarcoma-like appearance. Ductal adenocarcinoma was characterized
by tall columnar cells with abundant amphophilic to eosinophil cytoplasm. Pleomorphic sarcoma was characterized to have
overall glandular growth pattern, simulating a malignant phyllodes tumour. Estrogen and progesterone receptors showed nuclear
immunostaining in mesenchymal multinucleated giant cells. In conclusion, SC of the prostate is an exceedingly rare tumour.
Retrospective analyses render prostate SC as one of the most aggressive prostate malignancies. The prognosis is dismal regardless
of other histologic or clinical ﬁndings.
1.Introduction
Sarcomatoid carcinoma (SC) of the prostate is a very rare
neoplasia that display mixed epithelial and mesenchymal
diﬀerentiation [1, 2] .T h e r ei sc o n s i d e r a b l ec o n t r o v e r s yi n
the literature regarding nomenclature and histogenesis of
these tumours. Some authors use the term carcinosarcoma
(CS) if there are heterologous components and sarcomatoid
carcinoma if there are not [2, 3]. However, the most recent
World Health Organization classiﬁcation of urinary tract
tumour does not distinguish between SC and CS and use the
term “sarcomatoid carcinoma” to denote all of these lesions
[1]. Clinically, most patients are 70 years old (range 50–89)
and present with urinary tract obstruction and symptoms
of frequency, urgency, and nocturia [4]. In about half of
the cases, the initial diagnosis is acinar adenocarcinoma,
followed by hormonal and/or radiation therapy, with a
subsequent diagnosis of SC [5–9]. The mean time for the
development of SC after acinar adenocarcinoma is 3 years
[10, 11]. In published series, 5- and 7-year survivals were
41% and 14%, respectively [5, 6]. Another study showed
that the actuarial risk of death at 1 year after diagnosis of
sarcomatoid carcinoma was 20% [7].
We report the case of a 59-years-old man with unusual
histopathologic ﬁndings of prostate sarcomatoid carcinoma,
showing characteristics of ductal prostatic adenocarcinoma
and prostatic stromal sarcoma-like appearance (homologous
component). We also discuss the clinical, diagnostic, and
therapeutic aspects of this uncommon tumour.
2.CaseReport
A 59-year-old man presented to emergency with acute
urinary retention and perineal pain in December 2006.
He reported a previous history of hematuria and urinary
retentionanddeniedanyconstitutionalsymptoms. Ahistory
of frequent micturition, dysuria, poor urinary stream, and
nocturia of approximately 12-month duration was also
present. There was no family history of genitourinary cancer.
No exposure to hazardous chemicals was conﬁrmed.
Rectal examination revealed a moderately enlarged nor-
mal prostate gland, consistent with prostatic adenoma grade
2/3. There was no palpable lymphadenopathy, and the rest
of his physical examination was unremarkable. His last
PSA, obtained one month earlier by his primary care2 Case Reports in Urology
Table 1: Antibodies used for immunohistochemical studies.
Antigen Clone Dilution Pretreatment Tumour cell reactivity Source
Ki-67 MIB1 Prediluted pH6 Nuclear Dako, Carpinteria, Calif, USA
ER 1D5 1/35 pH6 Nuclear stromal cells Dako, Carpinteria, Calif, USA
PR PGR36 1/70 pH6 Nuclear stromal cells Dako, Carpinteria, Calif, USA
P-504 I3H4 Prediluted pH9 Epithelial cells Dako, Carpinteria, Calif, USA
PSA ERPR8 Prediluted pH6 Epithelial cells Dako, Carpinteria, Calif, USA
CK AE1/AE3 AE1/AE3 Prediluted pH6 Both components Dako, Carpinteria, Calif, USA
SMA HHF35 Prediluted pH6 Negative Dako, Carpinteria, Calif, USA
S-100 Polyclonal 1/3000 pH6 Negative Dako, Carpinteria, Calif, USA
CD34 QBEND-10 Prediluted pH6 Negative Dako, Carpinteria, Calif, USA
p63 4A4 Prediluted pH6 Nuclear Dako, Carpinteria, Calif, USA
β-GCH Polyclonal Prediluted pH9 Negative Dako, Carpinteria, Calif, USA
physicianaspartofroutineannualphysicalexamination,was
1.49ug/L. Since no pathology was found in both physical
examination and laboratory tests, he underwent in January
2007 retropubic adenomectomy by Millin’s technique with-
out complications. Due to the unexpected ﬁndings of the
pathology, the patient underwent further evaluation. Pelvic
MRIconsideredsuspiciousforextracapsularextensionofthe
tumour (Figure 1(a))a n dl y m p hn o d ea ﬀectation (extern
iliac). Computed tomography of chest and brain as well as
bone scan was negative for metastasis disease. The patient
received adriamycin and ifosfamide and hormone therapy.
Progression was conﬁrmed in January 2008, and local radio-
therapy was performed (39Gy) with partial response (50%).
In February 2009, hormone treatment was retired, and he
received Taxotere without clinical response. In October2010,
a rectovesical ﬁstula was conﬁrmed by progression disease
and uncontrolled lumbar pain (Figure 1(b)). A suprapubic
andepiduralcatheterswerecollocated.Thepatientremained
hospitalized to January 2011 with controlled pain and
progression disease status.
3.MaterialsandMethods
The excised specimen was ﬁxed in 10% buﬀered formalin
and processed for routine histopathological study. Immuno-
histochemistry was performed on paraﬃne m b e d d e dt i s s u e .
The thin-sliced materials were immunostained by EnVision
FLEX Kit and placed in a Dako Autostainer (EnVisionTM
Systems, DAKO, Carpinteria, Calif, USA). For speciﬁc imm-
unohistochemical details, see Table 1.
4. Results
4.1. Gross Pathology. Grossly, the biopsy consisted in varies
irregulars fragments, weighed 40gr. At cut sections there
were elastic with grey-white areas. Haemorrhage and necro-
sis areas were observed.
4.2. Microscopic Findings. Standard H&E histologic sec-
tions demonstrated a biphasic tumour consisted of ductal
adenocarcinoma (40%) and pleomorphic sarcoma (60%).
Ductal adenocarcinoma was characterized by tall columnar
cells with abundant amphophilic to eosinophil cytoplasm.
Focal pseudostratiﬁed layers were also seen (Figure 2(a) and
2(b)). There were numerous atypical mitosis, cytological
atypia, and areas of haemorrhage and necrosis. An admixed
of cribriform and solid patterns were present. In subjacent
stroma to epithelial areas, there were giant cells with
large, irregular, and hyperchromatic nuclei (Figure 2(b)).
The pleomorphic sarcoma was characterized to have overall
glandular growth pattern, simulating a malignant phyllodes
tumour (Figures 2(c)–2(f)). The malignant stroma showed
increased cellularity, pleomorphism, and numerous atypical
mitotic ﬁgures. No spindled, fascicular, or heterologous
growth pattern were presents.
Immunohistochemistry studies showed a focal expres-
sion to cytokeratin AE1/AE3 in stromal component
(Figure 3(a)). Proliferate index expression was moderate in
both components (Figure 3(b)). Estrogen and progesterone
receptors showed nuclear immunostaining in mesenchymal
multinucleated giant cells, with no reactivity at the epithelial
component (Figures 3(c) and 3(d)). A nuclear reactivity
was observed for p63 in both neoplastic epithelial and
mesenchymal component (Figures 3(e) and 3(f)). Ductal
adenocarcinoma showed expression for PSA and P504.
Both neoplastic epithelial and mesenchymal components
exhibited no staining for smooth muscle actin, desmin, S-
100 protein, CD34, and β-GCH.
5. Discussion
Sarcomatoid carcinoma, also termed carcinosarcoma and
spindle-cell carcinoma, is a rare biphasic malignancy in the
prostate [1–3]. The two elements of SC are a malignant
epithelial(carcinomatous)componentandamalignantmes-
enchymal (sarcomatous) component with the presence or
absence of heterologous elements [5–7]. The origin of these
tumours has been controversial. It is the consideration of
some investigators that SC is merely a collision of sarcoma
and carcinoma which develop independently in the prostate.
OtherinvestigatorshoweversuggestedthatbothcomponentsCase Reports in Urology 3
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Figure 1: (a) Pelvic MRI considered suspicious for extracapsular extension of the tumour. (b) Pelvic TC scan showed tumour with extents
hypodense zones, consistent with necrosis.4 Case Reports in Urology
(a) (b) (c)
(d) (e) (f)
Figure 2: Microscopic ﬁnding. (a) Typical histopathologic aspect of prostatic ductal adenocarcinoma, showing a cribiform pattern.
(b) Stroma with giant cells. (H-E, 50x–100x). (c, d, and e) Pleomorphic sarcoma characterized to have overall glandular growth pattern
(H-E, 50x-100x-200x). (f) Malignant stroma showed increased cellularity and pleomorphism. Note: no spindled, fascicular, or heterologous
growth pattern were presents. (H-E, 400x).
(a) (b) (c)
(d) (e) (f)
Figure 3: Immunohistochemical proﬁle. (a) Cytokeratin AE1/ae3 stain showing a strong reactivity in epithelial component and focal
expression is present at mesenchymal component (DAB, 100x). (b) Ki-67 nuclear positivity in both epithelial and mesenchymal component
(DAB, 100x). (c and d) Estrogen and progesterone receptor expression. Multinucleated stromal cells showing nuclear positivity (Circle)
(DAB, 400x). (e and f) p63 immunoreactivity in epithelial and stromal elements (DAB, 100x-200x).Case Reports in Urology 5
arise from an omnipotent cell [6, 11, 12]. In a study
using loss-of-heterozygosity analysis in sarcomatoid pro-
static adenocarcinoma, an evidence that the carcinomatous
and sarcomatous elements are clonally related supported
the hypothesis that a single malignant process underlies
the aetiology of sarcomatoid carcinoma of the prostate
[10]. Regardless its origin, the most recent World Health
Organization classiﬁcation of urinary tract tumours does
not distinguish between SC and CS and use the term
“sarcomatoid carcinoma” to denote all of these lesions [1].
Previous studies have showed a prior history of acinar
prostatic adenocarcinoma in 48% and 65% of patients with
sarcomatoid prostatic carcinoma [6, 7], and these ﬁndings
support, in these cases, a progression of the prior acinar
adenocarcinomatoahigher-gradetumour.Inourcase,there
was no previous history of prostatic neoplasia, and no aci-
nar adenocarcinoma was demonstrated. However, a ductal
prostatic carcinoma was present at the initial diagnostic, and
this variant is considered a higher-grade epithelial tumour.
Additionally, a low percentage (10%) of SCs show ductal
prostatic adenocarcinoma as part of epithelial component in
prostatic SC [7].
Microscopically, the carcinomatous and sarcomatous
components are admixed, with blending of the two in some
areas. Previous studies showed two kinds of sarcomatous
elements: undiﬀerentiated spindled type and heterologous
type [5–7, 12] .T h em a j o r i t yo fS Cd e m o n s t r a t e da n
undiﬀerentiated spindled appearance type (76%) and the
rest of the sarcomatoid component are heterologous type
(24%), that resembled osteosarcoma, chondrosarcoma, and
rhabdomyosarcoma [5–7]. In our case, sarcomatoid com-
ponent showed a homologous-like appearance, simulating
a malignant phyllodes tumour, characterized by stromal
overgrowth, cellularity, atypical stromal cells, inﬁltrative
pattern, and necrosis. To our knowledge, this sarcomatoid
component has not been previously informed. Indepen-
dently of the sarcomatoid-type ﬁnding, the prognosis seems
similar.
Byimmunohistochemistry, epithelialelementsreactwith
cytokeratins, PSA, and PSAP, whereas sarcomatoid elements
react with vimentin or speciﬁc markers corresponding to the
mesenchymal diﬀerentiation if present [5–7]. In our case,
we could demonstrate expression for cytokeratin AE1/AE3,
in both components but not PSA and P540 (only positive
at epithelial cells). Additionally, we obtained expression
for progesterone and estrogen receptors at mesenchymal
pleomorphiccells.Thisﬁndinghasbeendescribedinstromal
tumours of uncertain malignant potential (STUMP) and
stromal sarcoma [13]. Probably in our tumour, the hormone
expression at mesenchymal cells conﬁrm a homologous
diﬀerentiation as stromal sarcoma-like. Another immuno-
histochemicalﬁndingwasthenuclearexpressioninepithelial
and mesenchymal component for p63. In spindle cell lesions
of the urinary bladder, expression of several cytokeratins
with p63 could help to the diagnostic of sarcomatoid
carcinoma [14]. In our case, the expression of cytokeratin
and p63, coupled within the context of morphology, help to
reach ﬁnal diagnostic.
Due to the limited experience, there are no standard
treatment recommendations the management of CSs of the
prostate. Operable tumours are treated with surgery [6,
7]. Surgeries with curative intent include radical retropu-
bic prostatectomy, radical cystoprostatectomy, suprapubic
prostatectomy, and pelvic exenteration [6, 7]. Patient with
SC have poor prognosis, with an actual risk of death of 20%
within one year of diagnosis. In fact, nonsurgical therapy
(androgen ablation treatment and chemotherapy) seems
to be ineﬀective, and 55.5% of patients are unresponsive
to chemotherapy (taxotere, estramustine, carboplatinum,
or cisplatinum) [7]. In conclusion, SC of the prostate is
an exceedingly rare tumour. Retrospective analyses render
prostate SC as one of the most aggressive prostate malignan-
cies. The prognosis is dismal regardless of other histologic or
clinical ﬁndings.
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